Drug intelligence / Profile preview

letrozole + testosterone

Development stage: Preclinical
Lead developer: Novartis
Modality: Small Molecules
Administration: Subcutaneous

Overview

Letrozole + testosterone is a combination therapy that pairs an aromatase inhibitor (letrozole) with testosterone. Letrozole works by inhibiting the enzyme aromatase, which converts androgens to estrogens, thereby reducing estrogen production. When combined with testosterone, this therapy creates a hormonal environment with increased testosterone levels and decreased estrogen levels. This combination has been studied in various clinical contexts including breast cancer treatment, male hypogonadism, obesity-related testosterone deficiency, and immunomodulation.

Targets

AR (Adrenergic receptors)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on letrozole + testosterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on letrozole + testosterone.

Explore the full profile